James D. Berry - Publications

Affiliations: 
Neurology MGH & Harvard Medical School, Boston, MA, United States 

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Wills AM, Garry J, Hubbard J, Mezoian T, Breen CT, Ortiz-Miller C, Nalipinski P, Sullivan S, Berry JD, Cudkowicz M, Paganoni S, Chan J, Macklin EA. Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. Bmc Neurology. 19: 104. PMID 31142272 DOI: 10.1186/s12883-019-1330-6  0.64
2019 Berry JD, Paganoni S, Carlson K, Burke K, Weber H, Staples P, Salinas J, Chan J, Green JR, Connaghan K, Barback J, Onnela JP. Design and results of a smartphone-based digital phenotyping study to quantify ALS progression. Annals of Clinical and Translational Neurology. 6: 873-881. PMID 31139685 DOI: 10.1002/acn3.770  1
2019 van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, Corcia P, Genge A, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. PMID 30850440 DOI: 10.1212/WNL.0000000000007242  0.64
2019 Pattee GL, Plowman EK, Garand KLF, Costello J, Brooks BR, Berry JD, Smith RA, Atassi N, Chapin JL, Yunusova Y, McIlduff CE, Young E, Macklin EA, Locatelli ER, Silani V, et al. PROVISIONAL BEST PRACTICES GUIDELINES FOR THE EVALUATION OF BULBAR DYSFUNCTION IN ALS. Muscle & Nerve. PMID 30620104 DOI: 10.1002/mus.26408  1
2018 Stipancic KL, Yunusova Y, Berry JD, Green JR. Minimally Detectable Change and Minimal Clinically Important Difference of a Decline in Sentence Intelligibility and Speaking Rate for Individuals With Amyotrophic Lateral Sclerosis. Journal of Speech, Language, and Hearing Research : Jslhr. 1-15. PMID 30383220 DOI: 10.1044/2018_JSLHR-S-17-0366  1
2018 Green JR, Allison KM, Cordella C, Richburg BD, Pattee GL, Berry JD, Macklin EA, Pioro EP, Smith RA. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in persons with ALS: A quantitative speech analysis. British Journal of Clinical Pharmacology. PMID 30152872 DOI: 10.1111/bcp.13745  1
2018 Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, ... ... Berry JD, et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 97: 1268-1283.e6. PMID 29566793 DOI: 10.1016/j.neuron.2018.02.027  0.68
2017 Pattee GL, Plowman EK, Brooks BR, Berry JD, Atassi N, Chapin JL, Garand K, Yunusova Y, Mcilduff CE, Young E, Costello JM, Macklin EA, Locatelli ER, Silani V, Heitzman D, et al. Best practices protocol for the evaluation of bulbar dysfunction: summary recommendations from the NEALS bulbar subcommittee symposium. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-2. PMID 29205054 DOI: 10.1080/21678421.2017.1404109  1
2017 Berry JD, Paganoni S, Atassi N, Macklin EA, Goyal N, Rivner M, Simpson E, Appel S, Grasso DL, Mejia NI, Mateen F, Gill A, Vieira F, Tassinari V, Perrin S. Phase IIA Trial of Fingolimod for ALS Demonstrates Acceptable Acute Safety and Tolerability. Muscle & Nerve. PMID 28662296 DOI: 10.1002/mus.25733  0.64
2017 Allison KM, Yunusova Y, Campbell TF, Wang J, Berry JD, Green JR. The diagnostic utility of patient-report and speech-language pathologists' ratings for detecting the early onset of bulbar symptoms due to ALS. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-9. PMID 28355886 DOI: 10.1080/21678421.2017.1303515  1
2016 Rong P, Yunusova Y, Wang J, Zinman L, Pattee GL, Berry JD, Perry B, Green JR. Predicting Speech Intelligibility Decline in Amyotrophic Lateral Sclerosis Based on the Deterioration of Individual Speech Subsystems. Plos One. 11: e0154971. PMID 27148967 DOI: 10.1371/journal.pone.0154971  1
2015 Ratti E, Berry JD, Greenblatt DJ, Loci L, Ellrodt AS, Shefner JM, Cudkowicz ME. Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone. Toxicology Reports. 2: 1396-1403. PMID 26705515 DOI: 10.1016/j.toxrep.2015.09.010  0.68
2015 Salameh JS, Brown RH, Berry JD. Amyotrophic Lateral Sclerosis: Review. Seminars in Neurology. 35: 469-76. PMID 26502769 DOI: 10.1055/s-0035-1558984  0.68
2015 Nicholson KA, Cudkowicz ME, Berry JD. Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All? Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 12: 376-83. PMID 25700798 DOI: 10.1007/s13311-015-0341-2  0.68
2015 Shellikeri S, Yunusova Y, Green JR, Pattee GL, Berry JD, Rutkove SB, Zinman L. Electrical impedance myography in the evaluation of the tongue musculature in amyotrophic lateral sclerosis. Muscle & Nerve. PMID 25580728 DOI: 10.1002/mus.24565  1
2014 Schwartz JC, Podell ER, Han SS, Berry JD, Eggan KC, Cech TR. FUS is sequestered in nuclear aggregates in ALS patient fibroblasts. Molecular Biology of the Cell. 25: 2571-8. PMID 25009283 DOI: 10.1091/mbc.E14-05-1007  0.68
2014 Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, Jaffa M, Milburn MV, Ryals JA, Bowser R, Cudkowicz ME, Berry JD. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 15: 362-70. PMID 24984169 DOI: 10.3109/21678421.2014.908311  0.68
2014 Berry JD, Korngut L. Reevaluating the risk of DVT in people with ALS: weak in the knees and DVTs. Neurology. 82: 1668-9. PMID 24727310 DOI: 10.1212/WNL.0000000000000420  0.68
2014 Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SS, Sandoe J, Perez NP, Williams LA, Lee S, Boulting G, Berry JD, Brown RH, Cudkowicz ME, Bean BP, Eggan K, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Reports. 7: 1-11. PMID 24703839 DOI: 10.1016/j.celrep.2014.03.019  0.68
2014 Berry JD, Cudkowicz ME, Shefner JM. Predicting success: optimizing phase II ALS trials for the transition to phase III. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 15: 1-8. PMID 24588460 DOI: 10.3109/21678421.2013.838969  0.68
2013 Bucheli ME, Calderón A, Chicaiza D, Franco C, López R, Digga E, Atassi N, Salameh J, Berry JD. Feedback interaction of research, advocacy, and clinical care applied to ALS research in South America. Neurology. 81: 1959-61. PMID 24276333 DOI: 10.1212/01.wnl.0000436610.28210.a5  0.68
2013 Green JR, Yunusova Y, Kuruvilla MS, Wang J, Pattee GL, Synhorst L, Zinman L, Berry JD. Bulbar and speech motor assessment in ALS: challenges and future directions. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14: 494-500. PMID 23898888 DOI: 10.3109/21678421.2013.817585  0.68
2013 Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, et al. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. Plos One. 8: e61177. PMID 23613806 DOI: 10.1371/journal.pone.0061177  0.68
2013 Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, Dong Y, Ingersoll EW, Archibald D. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14: 162-8. PMID 23323713 DOI: 10.3109/21678421.2012.762930  0.68
2013 Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14: 44-51. PMID 22985432 DOI: 10.3109/17482968.2012.723723  0.68
2012 Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, Bowser R, Lawson R, Jaffa M, Milburn MV, Ryals JA, Berry JD. Biochemical alterations associated with ALS. Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group On Motor Neuron Diseases. 13: 110-8. PMID 22117131 DOI: 10.3109/17482968.2011.619197  0.68
2005 Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster Neurology. 65: 444-447. PMID 16087911 DOI: 10.1212/01.WNL.0000168259.94991.8a  0.68
2004 Berry JD, Rowbotham MC, Petersen KL. Complex regional pain syndrome-like symptoms during herpes zoster Pain. 110. PMID 15275746 DOI: 10.1016/j.pain.2003.12.038  0.68
Show low-probability matches.